- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-02-01-2019
Pharmaceutical Executive
Q&A: Regulatory Reform in China
February 19, 2019
Features
39
2
Dr. Lingshi Tan, a director at DIA, and chairman and CEO of Shanghai-based CRO dMed Company Limited, which he founded after establishing R&D operations for Pfizer in China, discusses the nation's regulatory evolution and opportunities for its government to strengthen collaborations with FDA and other leading global agencies.
China: A Change in Attitude
February 10, 2019
Features
39
2
How innovation growth has upped the pressure on China to compete globally, forcing upgrades in regulatory, quality, and standards.
New Roads to China
February 09, 2019
Features
39
2
How the nation’s rapidly changing regulatory climate is creating a new landscape for pharmaceutical service providers
Closing the Pharma and Digital Health Divide
February 08, 2019
Columns
39
2
Event-hopping from big biz to high tech leaves same takeaway: Adaptive leadership-not innovation-is key to future synergy.
A Leading Man’s Next Act
February 08, 2019
Features
39
2
Pharm Exec profiles Dr. Xiaobin Wu, an accomplished leader in helming China operations at big pharmas such as Pfizer and Bayer, who believes his recent jump to biotech as GM of China and president of BeiGene will deliver his most lasting legacy.
Two Steps Forward
February 08, 2019
From the Editor
39
2
Green-lighting China as our coverage focus in the February issue wasn't without conflict or hesitation, but as our reporting of the nation's biopharma landscape shows, perseverance and growth many times go hand-in-hand.
Let the Drug Pricing Games Begin
February 07, 2019
Columns
39
2
Drug importing, advertising, rebates, and industry practices are on the table as legislators zero in on pharma pricing strategies.
Mixed Outlook for China Life Sciences
February 06, 2019
Features
39
2
Momentum and uncertainty shape the sector's economic picture.
CFIUS Reform’s Impact on Biopharma
February 06, 2019
Features
39
2
What the new rules mean for Chinese-related investments and acquisitions in the US.
Op-Ed: Opening the Golden Door
February 01, 2019
Columns
39
2
The talent and tenacity of immigrants can help drive the life sciences industry into the future, if we have the will and the wisdom to encourage it.
Pharmaceutical Executive, February 2019 Issue (PDF)
February 01, 2019
Issue PDF
39
2
Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.
Country Report: Spain
February 01, 2019
Special Sponsored Section
39
2
With Spain now squarely on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top-tier investment destination once more.